Tandem Diabetes Care INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Tandem Diabetes Care reported increased worldwide sales to over $1 billion in 2025, driven by higher pump shipments and international expansion, despite incurring significant net operating losses.
NASDAQ
Tandem Diabetes Care's 2024 10-K filing reveals a year of strategic transitions, including portfolio expansion and international growth, alongside ongoing financial challenges and evolving market dynamics.
NASDAQ
Tandem Diabetes Care's 10-K filing details its capital stock, potential risks, and strategic direction in the competitive diabetes technology market.